Milestone Pharmaceuticals IncNASDAQ:MIST
- LAST PRICE1.3400
- TODAY'S CHANGE (%)0.0500 (3.8760%)
- Bid / Lots1.3400/ 1
- Ask / Lots1.3500/ 10
- Open / Previous Close1.3000 / 1.2900
- Day Range
- 52 Week Range
- Volume60,280
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIST |
|---|---|---|
| 09:32 ET | 392 | 1.3 |
| 09:34 ET | 787 | 1.29 |
| 09:36 ET | 5060 | 1.29 |
| 09:38 ET | 2713 | 1.29 |
| 09:43 ET | 100 | 1.2978 |
| 09:45 ET | 9477 | 1.28 |
| 09:48 ET | 180 | 1.27 |
| 09:50 ET | 2000 | 1.2701 |
| 09:52 ET | 2500 | 1.28 |
| 09:57 ET | 9562 | 1.31 |
| 09:59 ET | 21579 | 1.33 |
| 10:01 ET | 200 | 1.34 |
Jun 12, 2024
May 31, 2024
Milestone(R) Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference, from 8:00AM ET on Friday May 31, 2024 by Dow Jones
8:00AM ET on Friday May 31, 2024 by Dow Jones
May 30, 2024
DJ Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co., from 7:23AM ET on Thursday May 30, 2024 by Dow Jones
7:23AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST(TM), from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Milestone Pharmaceuticals Inc | 68.7M | -1.1x | --- |
MediciNova Inc | 69.6M | -8.0x | --- |
enVVeno Medical Corp | 69.3M | -3.0x | --- |
Benitec Biopharma Inc | 67.3M | -0.7x | --- |
Leap Therapeutics Inc | 69.6M | -0.8x | --- |
Serina Therapeutics Inc | 70.8M | -0.6x | --- |
Company Information
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Contact Information
- Headquarters
- 420-1111 boul. Dr.-Frederik-PhilipsMONTREAL, QC, Canada H4M 2X6
- Phone
- 514-336-0444
- Fax
- 514-336-0444
Executives
- Non-Executive Independent Chairman of the Board
- Robert Wills
- President, Chief Executive Officer, Director
- Joseph Oliveto
- Chief Financial Officer, Executive Vice President of Corporate Development
- Amit Hasija
- Chief Operating Officer
- Jeffrey Nelson
- Chief Medical Officer
- David Bharucha
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.63 |
EPS | $-1.25 |
Book Value | $0.50 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
